Simulations Plus, Inc.
Close on Oct 7, 2026
- Market cap
- $374.42M
- P/E (TTM)
- 46.3
- Dividend yield
- –
About Simulations Plus
Services-Computer Integrated Systems Design, SIC 7373
Simulations Plus, Inc. develops modeling and simulation software and provides scientific consulting services to support the pharmaceutical, biotechnology, agrochemical, cosmetics, and food industries, as well as academic and regulatory agencies. The company operates through two segments, Software and Services, assisting clients from early drug discovery through clinical trials and regulatory approval. Its software offerings include biosimulation platforms such as ADMET Predictor, GastroPlus, DDDPlus, and specialized disease-modeling tools like DILIsym. In addition, its consulting services encompass pharmacokinetic and pharmacodynamic modeling, quantitative systems pharmacology, physiologically based pharmacokinetic analysis, and clinical operations support.
The company is headquartered in Research Triangle Park, North Carolina, and operates a European office in Paris, France. Simulations Plus serves a global client base, conducting business across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region.
Summary of the business section of Simulations Plus's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Simulations Plus, Inc.
- Founded
- 1996
- Headquarters
- Durham, NC
- Address
- 600 Park Offices Drive, Suite 300 #4134 27713
- Phone
- (661) 723-7723
- Website
- www.simulations-plus.com
- Employees
- 213, Aug 31, 2025
- Industry
- Services-Computer Integrated Systems Design
- Fiscal year ends
- August 31
- Auditor
- Rose, Snyder & Jacobs LLP, Encino, California
Stock & identifiers
- Ticker
- SLP
- Exchange
- Nasdaq
- IPO date
- Jun 19, 1997
- Shares outstanding
- 20M, Jun 30, 2026
- Public float
- $478.93M, Feb 28, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1023459
- CUSIP
- 829214105
- ISIN
- US8292141053
- LEI
- 529900KYRDJAQ8TJCG93
- EIN
- 95-4595609
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John Anthony DiBella II | Chief Revenue Officer | 85,140 |
| Jill Fiedler-Kelly | President, Services Solutions | 77,817 |
| Shawn Oconnor | Chief Executive Officer | 0 |
| William W. Frederick | EVP/CFO | 2,100 |
| Walter S. Woltosz | Director | 3,267,800 |
| Sharlene Evans | Director | 17,173 |
| John Kenneth Paglia | Director | 14,589 |
| Daniel L. Weiner | Director | 16,547 |
| Lisa LaVange | Director | 9,968 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Shawn OConnor. | $1.10M | -$15.17K | $481.53K | $24 | $44 |
| FY2024 Shawn OConnor. | $1.66M | $1.39M | $815.44K | $62 | $53 |
| FY2023 Shawn OConnor. | $1.94M | $1.48M | $745.28K | $76 | $110 |
| FY2022 Shawn OConnor. | $1.34M | $2.23M | $464.46K | $102 | $117 |
| FY2021 Shawn OConnor. | $1.07M | $693.67K | $554.39K | $75 | $155 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of August 31, 2025, we employed 213 people, including 212 full-time and one part-time employee.”
Corporate history
Events identified from SEC filings